Grifols, S.A. (GRFS:NASDAQ) closed at $7.64 on October 16, 2026, up 1.33% on the day. The stock trades 22.8% below its 52-week high of $9.90 and 9.8% above its 52-week low of $6.96. Over the past year, it lost 20.8%. Grifols, S.A. is part of the Health Care sector (Major Pharmaceuticals).
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| +3.66% | +3.24% | +0.39% | -9.80% | -20.83% |
In 252 trading sessions since October 16, 2025, GRFS closed higher on 119 days (47%). Its best day was August 19, 2026 (+6.45%) and its worst was November 5, 2025 (-6.40%). It never moved 10% or more in a single session.
Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, Canada, and internationally. It specializes in providing infusion solutions, nutrition products, medical devices, and diagnostic instrumentation and reagents for use in hospitals and clinics. The company operates through four divisions: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience division manufactures and sells plasma derivatives for therapeutic use, such as the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. This division offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic division focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments and reagents for diagnostics, as well as blood bank products. This division primarily serves blood donation centers, clinical analysis laboratories,...
Find more stocks like GRFS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.